---
title: "Tango Therapeutics | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286312013.md"
datetime: "2026-05-13T20:23:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286312013.md)
  - [en](https://longbridge.com/en/news/286312013.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286312013.md)
---

# Tango Therapeutics | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0, missing the estimate of USD 578.09 K.

EPS: As of FY2026 Q1, the actual value is USD -0.32, missing the estimate of USD -0.3142.

#### Cash Position and Runway

Tango Therapeutics, Inc. held $379.8 million in cash, cash equivalents, and marketable securities as of March 31, 2026, which is expected to fund operations into 2028, beyond anticipated key data inflection points.

#### Collaboration Revenue

Collaboration revenue was $0 for the three months ended March 31, 2026, a decrease from $5.4 million for the same period in 2025.

#### Operating Expenses

Research and development expenses were $33,534 thousand for the three months ended March 31, 2026, down from $36,442 thousand in the prior year period. This change was primarily due to decreased spending from the discontinuation of the TNG908 clinical program, reduced development costs for TNG961, and lower discovery program, personnel-related, and facilities-related costs, partially offset by increased spending on vopimetostat and TNG456 clinical programs. General and administrative expenses increased to $15,235 thousand for the three months ended March 31, 2026, from $11,480 thousand for the same period in 2025, mainly due to increased personnel-related costs, including share-based compensation expense. Total operating expenses were $48,769 thousand for the three months ended March 31, 2026, compared to $47,922 thousand for the same period in 2025.

#### Profitability

Loss from operations was - $48,769 thousand for the three months ended March 31, 2026, compared to - $42,530 thousand for the same period in 2025. Other income, net, was $3,256 thousand in Q1 2026, up from $2,688 thousand in Q1 2025. Loss before income taxes was - $45,513 thousand for the three months ended March 31, 2026, versus - $39,842 thousand for the same period in 2025. The provision for income taxes was - $1 thousand in Q1 2026, compared to - $34 thousand in Q1 2025. Net loss for the three months ended March 31, 2026, was - $45,514 thousand, compared to a net loss of - $39,876 thousand in the same period in 2025.

#### Per Share Data

Net loss per common share – basic and diluted – was - $0.32 for the three months ended March 31, 2026, an improvement from - $0.36 per share in the same period in 2025. The weighted average number of common shares outstanding – basic and diluted – increased to 143,576,292 in Q1 2026 from 110,301,256 in Q1 2025.

#### Balance Sheet Highlights (as of March 31, 2026)

-   Cash and cash equivalents: $157,828 thousand.
-   Marketable securities: $222,011 thousand.
-   Total current assets: $392,327 thousand.
-   Total assets: $435,792 thousand.
-   Total current liabilities: $14,330 thousand.
-   Total liabilities: $44,286 thousand.
-   Total stockholders’ equity: $391,506 thousand.

#### Outlook / Guidance

Tango Therapeutics, Inc. anticipates presenting initial phase 1⁄2 data from the vopimetostat + RAS(ON) inhibitors combination study in 2026, which may inform a path to a pivotal trial in 1L pancreatic cancer. The company also expects to provide updates on vopimetostat monotherapy data in lung cancer and initial TNG456 data in glioblastoma in 2026. Additionally, a phase 1⁄2 vopimetostat + ERAS-0015 combination study is planned to initiate in the second half of 2026.

### Related Stocks

- [TNGX.US](https://longbridge.com/en/quote/TNGX.US.md)

## Related News & Research

- [Vanguard Group Inc. Has $59.81 Million Holdings in Tango Therapeutics, Inc. $TNGX](https://longbridge.com/en/news/286550878.md)
- [354,192 Shares in Tango Therapeutics, Inc. $TNGX Bought by Mass General Brigham Inc](https://longbridge.com/en/news/283483511.md)
- [Capital City Bank Group posts Q1 2026 investor presentation on website](https://longbridge.com/en/news/286599786.md)
- [Auburn National Bancorporation declares $0.27 quarterly dividend payable June 25](https://longbridge.com/en/news/286281680.md)
- [Apollo Clarifies Legal Status of Recent 8-K Disclosure](https://longbridge.com/en/news/286564452.md)